By inhibiting the PD-1/PD-L1 and CTLA-4 pathways, ICIs enhance T-cell-mediated anti-tumor immunity but can also lead to immune dysregulation, resulting in irAEs such as IMLI (5, 6, 17). Here, CTLA4 is linked to neoplasm.